Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Integrated Diagnostics Holdings ( (GB:IDHC) ) just unveiled an announcement.
Integrated Diagnostics Holdings posted a 31% year-on-year rise in first-quarter 2026 revenue to EGP 2.1 billion, driven by a 22% increase in test volumes and higher pricing and service mix, particularly in Egypt. The group’s expanding 794-branch network boosted patient numbers and utilisation, while gross profit and EBITDA rose 28% and 23% respectively, even as Ramadan seasonality, new branch pre-operating costs and investments in Saudi Arabia and radiology compressed margins.
Net profit surged 78% to EGP 437 million, or 36% on an adjusted basis excluding foreign-exchange gains, underscoring robust underlying profitability and cost discipline. Growth was broad-based across Egypt, Jordan and Nigeria, with Saudi Arabia gaining traction, and the company ended the quarter with a higher net cash balance, reinforcing its financial flexibility and strengthening its competitive position in regional diagnostics.
More about Integrated Diagnostics Holdings
Integrated Diagnostics Holdings is a regional healthcare company focused on medical testing and diagnostic services across Egypt, Jordan, Nigeria, Saudi Arabia and Sudan. Operating under brands such as Al Borg and Biolab, it runs a large branch network offering laboratory tests, radiology and specialised diagnostics, with Egypt contributing the bulk of its revenue.
Average Trading Volume: 167,850
Technical Sentiment Signal: Buy
Current Market Cap: $325.5M
For detailed information about IDHC stock, go to TipRanks’ Stock Analysis page.